Abstract:Accumulated evidence supports that long non-coding RNAs (lncRNAs) are involved significantly in the development of human cancers. Enhancer RNAs (eRNAs), a subtype of lncRNAs, have recently attracted much attention about their roles in carcinogenesis. Colon adenocarcinoma is one of the most commonly diagnosed tumors with unfavorable prognosis. It highlights the great significance of screening and identifying novel biomarkers. More importantly, it remains to be elucidated with respect to the function of eRNAs in colon adenocarcinoma, as is in pan-cancers. The expression of LINC02257 was determined based on the data obtained from The Cancer Genome Atlas (TCGA). Further evaluation was performed on the basis of the following analyses: clinicopathology and survival analysis, gene ontology (GO) terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, as well as multi-omics immunotherapy-related analysis and co-expression analysis. The statistical analysis was conducted in R software, and immune cell infiltration of LINC02257 expression in cancers was investigated by using the CIBERSORT algorithm. By large-scale data mining, our study highlighted that a total of 39 eRNA genes were associated with colon adenocarcinoma prognosis, among which 25 eRNAs showed significant associations with their predicted target genes. LINC02257 was identified as the most significant survival-associated eRNA, with DUSP10 as its target gene. Besides, the high expression of LINC02257 in colon adenocarcinoma was more vulnerable to unfavorable prognosis and correlated with various clinical characteristics. GO and KEGG analyses revealed that LINC02257 was closely correlated with extracellular matrix organization via the PI3K-Akt signaling pathway. Besides, LINC02257 expression correlated with a multi-omics analysis of 33 cancer types, such as survival analysis [overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI)] and immunotherapy-related analysis [tumor microenvironment (TME), tumor mutational burden (TMB), and microsatellite instability (MSI)]. Finally, we investigated the co-expression genes of LINC02257 and its potential signaling pathways across different cancer types. LINC02257 is screened and can function as an independent prognostic biomarker through the PI3K-Akt signaling pathway for colon adenocarcinoma. Simultaneously, LINC02257 may be a multifaceted and significant immunotherapy-related eRNA in different cancers.

A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma

Role of HAND2-AS1 in human tumors

Long Non-Coding RNA HAND2-AS1 Delays Cervical Cancer Progression Via Its Regulation on the Microrna-21-5p/timp3/vegfa Axis.

Long Noncoding RNA HAND2-AS1 Suppresses Cell Proliferation, Migration, and Invasion of Bladder Cancer Via Mir-17-5p/klf9 Axis.

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

LncRNA HAND2-AS1 Exerts Anti-Oncogenic Effects on Ovarian Cancer Via Restoration of BCL2L11 As a Sponge of Microrna-340-5p

LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.

LncRNA HAND2-AS1 Inhibits 5-Fluorouracil Resistance by Modulating Mir-20A/pdcd4 Axis in Colorectal Cancer.

LncRNA HAND2-AS1 Inhibited Colon Cancer Progression By Regulating miR-3118/ZG16 Axis

Expression, Prognosis Value, and Immune Infiltration of Lncrna ASB16-AS1 Identified by Pan-Cancer Analysis

Epigenetic Silencing and Tumor Suppressor Gene of HAND2 by Targeting ERK Signaling in Colorectal Cancer

Computational Recognition of LncRNA Signatures in Tumor-Associated Neutrophils Could Have Implications for Immunotherapy and Prognostic Outcome of Non-Small Cell Lung Cancer

HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis

Comprehensive analysis identifies long non-coding RNA RNASEH1-AS1 as a potential prognostic biomarker and oncogenic target in hepatocellular carcinoma

HAND2-AS1 plays a tumor-suppressive role in hepatoblastoma through the negative regulation of CDK1

An Immune-Related Lncrna Signature As a Prognostic Immunotherapy Target for Colon Cancer

LncRNA WTAPP1 Promotes Cancer Cell Invasion and Migration in NSCLC by Downregulating Lncrna HAND2-AS1

Linc02257, An Enhancer Rna Of Prognostic Value In Colon Adenocarcinoma, Correlates With Multi-Omics Immunotherapy-Related Analysis In 33 Cancers

Overexpression of Long Non-Coding RNA Colon Cancer-Associated Transcript 2 is Associated with Advanced Tumor Progression and Poor Prognosis in Patients with Colorectal Cancer.

Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment

The roles of lncRNA AP001469.3 in clinical implications, immune landscape and carcinogenesis of colorectal cancer